Investigational Drug Details
| Drug ID: | D478 |
| Drug Name: | GFT505 |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 completed (NCT01694849) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0243 | NCT01694849 | Phase 2 | Completed | No Results Available | September 2012 | January 14, 2016 | Details |
| L0592 | EUCTR2015-005385-38-BE | Phase 3 | Not Recruiting | No Results Available | 29/01/2016 | 16 November 2020 | Details |
| L0651 | EUCTR2012-000295-42-BE | Phase 2 | Not Recruiting | No Results Available | 16/08/2012 | 22 August 2016 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A04818 | 33494735 | BMC Complement Med Ther | Yellow loosestrife (Lysimachia vulgaris var. davurica) ameliorates liver fibrosis in db/db mice with methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis. | Details |
| A05245 | 33326461 | PLoS One | The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model. | Details |
| A07174 | 32592770 | Eur J Pharmacol | Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis. | Details |
| A18692 | 26997214 | Saudi J Gastroenterol | Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. | Details |
| A21635 | 25164277 | Expert Opin Investig Drugs | GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. | Details |
| A23532 | 23703580 | Hepatology | Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. | Details |
| A45599 | 23715754 | Diabetes Care | Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. | Details |